Tuesday, February 24th, 2026

FOR IMMEDIATE RELEASE

HEXTAR HEALTHCARE REPORTS NET LOSS OF RM31.4 MILLION IN THE FOURTH QUARTER OF 2025

In its latest financial results released today, Hextar Healthcare Berhad and its subsidiary companies ("HHB" or the "Group") posted a net loss of RM31.4 million, on the back of RM35.5 million in revenue for the period ended December 31st, 2025. Comparatively, its net loss was RM8.0 million against revenue of RM41.6 million in the same period of the preceding year. In terms of revenue, HHB recorded a slight increase in full-year turnover, from RM147.0 million previously, to RM148.1 million in the financial year just ended. However, its cumulative net loss for the year stood at RM45.0 million, up from loss of RM13.9 million reported in the previous year while loss per share stood at 4.1 sen in the current financial year, compared to 1.3 sen previously.

The Group acknowledges that it has been another challenging year for the glove and healthcare industries as it contended with soft market demand, low plant utilisation rates as well as the strong Ringgit against USD exchange rate. Aside from this, HHB also recognised a deferred tax asset adjustment of RM10.7 million as well as an impairment loss on investment of RM11.6 million in the current financial quarter. Despite these short-term setbacks, the Group remains committed to the business and is optimistic of its future prospects. HHB's Managing Director, Mr. Khoo Chin Leng, shares, "whilst the Group has taken active steps to address the current soft demand and prices amidst an environment compounded by global trade and supply chain uncertainties, we are confident that such necessary actions will pave the way for improved performance over the long term." Mr. Khoo adds that while HHB expects the glove market to recover progressively, the Group remains committed to positioning itself as a leading player in the healthcare industry through continuous innovation and growth.

Notwithstanding the Group's established glove and medical device operations, HHB's strategic move into property investment via Hextar World at Empire City, is geared for further headway since its soft launch in end-November 2025. Reflecting on this significant milestone, HHB's largest shareholder, Dato' Eddie Ong Choo Meng remarks, "Taking advantage of the nation's robust growth in the commercial and retail sectors, our investment is poised to secure an alternative income stream for the Group. Hextar World is primed for a key presence in the retail scene, offering a unique mix of entertainment, lifestyle, learning and culture for the community and population in Klang Valley. We remain committed to delivering long-term solid returns to our shareholders via this investment."

About Hextar Healthcare Berhad

Hextar Healthcare Berhad, *formerly known as Rubberex Corporation (M) Berhad*, was incorporated in Malaysia under the Companies Act 2016 as a private limited company on January 4th, 1996. It was initially listed on the Second Board of Bursa Malaysia Securities Berhad on April 16th, 1997, and subsequently transferred to the Main Board of Bursa Malaysia Securities Berhad on April 11th, 2005.

The principal activity of Hextar Healthcare Berhad is investment holding whilst its subsidiary companies are mainly involved in the manufacturing and sales of household gloves, industrial gloves and nitrile disposable gloves to more than 100 countries around the world. The Group is also involved in the manufacturing and sales of innovative in-vitro diagnostic (IVD) rapid test kits, enzyme-linked immunosorbent assay (ELISA) test kits specializing in infectious diseases diagnosis and drug-of-abuse screening for medical professionals and the clinical diagnostics markets. With the European continent being its largest customer base, Hextar Healthcare Berhad also operates an overseas marketing office/warehouse in Valencia, Spain.

The Group's headquarters and manufacturing plant is in Ipoh, Perak.

For more information on Hextar Healthcare Berhad, please visit the following websites:
www.hextarhealthcare.com and www.reszonics.com.

Contact:
Stephanie Hew
VP (Corporate Affairs & Investor Relations)
Email: stephanie.hew@hextar.com
Tel: +60 5 5482723/+60 12 3118175